What is metastatic hormone-resistant prostate cancer?

Metastatic hormone-resistant prostate cancer actually refers to metastatic castration-resistant prostate cancer (mCRPC), which is a stage where the disease progresses despite androgen deprivation therapy. This stage is common in the progression of prostate cancer and poses significant challenges for treatment. The details are as follows:

Prostate cancer is a malignant tumor originating in the prostate gland. The disease typically has a long course and generally progresses through several stages: localized prostate cancer, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer. In its early stages, prostate cancer often causes no obvious symptoms, and many patients already have distant metastases at initial diagnosis. After standard treatment with androgen deprivation therapy, most patients eventually progress to metastatic castration-resistant prostate cancer. At this point, further hormonal treatments are usually ineffective. Doctors typically recommend alternative therapies such as chemotherapy with docetaxel injection or abiraterone acetate tablets, or surgical interventions including bilateral orchidectomy or radical prostatectomy.

Patients with metastatic castration-resistant prostate cancer are advised to seek timely medical care and actively follow their doctors' recommended treatments, which may help improve their quality of life.